sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta Therapeutics, FDA and Elevidys

· 1h · on MSN

Sarepta Soars After FDA Says Some Patients Can Get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

Continue reading

· 28m · on MSN

Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume

· 13h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

2h

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...

3don MSN

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...

1don MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results